Observational studyPharmacology research & perspectives2026
Magnitude, Preventability, and Determinants of Adverse Drug Reactions Among Hospitalized Obstetric Patients in Ethiopia: A Prospective Observational Study.
Observational study in Pharmacology research & perspectives, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adverse drug reactions (ADRs) are an important and potentially preventable cause of morbidity among hospitalized obstetric patients, with implications for both maternal and fetal safety, yet evidence from low-resource settings remains limited. This prospective observational study, conducted from February to May 2025 at Debre Tabor Comprehensive Specialized Hospital, Ethiopia, aimed to determine the magnitude, characteristics, preventability, and determinants of ADRs among hospitalized pregnant women and postpartum women within six weeks of delivery. ADRs were identified through daily chart review and patient interviews and confirmed using the Naranjo Adverse Drug Reaction Probability Scale, while severity and preventability were assessed using the modified Hartwig and Siegel scale and the Schumock and Thornton criteria, respectively. Multivariate logistic regression was used to identify factors independently associated with ADR occurrence. Among the 354 patients included, 52 experienced at least one ADR, yielding a prevalence of 14.7%. Most ADRs were mild to severe (88.5%) and classified as definitely preventable (82.7%). Polypharmacy (4-6 medications) was independently associated with ADR occurrence (adjusted odds ratio [AOR] = 4.02; 95% CI: 1.63-9.93). Additionally, patients with a history of adverse pregnancy outcomes (AOR = 6.28; 95% CI: 2.64-14.95) and those with underlying medical comorbidities (AOR = 2.95; 95% CI: 2.23-9.76) had significantly higher odds of experiencing ADRs. ADRs were relatively common among hospitalized obstetric patients, and the predominance of preventable events highlights the need for strengthened pharmacovigilance systems and targeted medication safety interventions to reduce preventable harm and improve maternal and fetal outcomes in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.